pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
Company details
- Status
- Public
- HQ
- 770 Lindaro Street, San Rafael, CA 94901, US
- Founded
- 1997
- Employees
- 3,171
- Programs
- 91
- Drugs
- 36
- Patents
- 175
BMN 165 (rAvPAL-PEG)
Phase 2 · mab · Phenylketonuria
BMN 165 (rAvPAL-PEG) for Phenylketonuria is a Phase 2 program (mab) at BioMarin Pharmaceutical Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code 165-205
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BioMarin Pharmaceutical Australia Pty Ltd
- Phase
- Phase 2
- Modality
- mab
- Indication
- Phenylketonuria
- Status
- completed
- Trials
- 1